p14^(ARF)、p53蛋白表达与H101治疗鼻咽癌疗效的关系  

Relationship between the expressions of p14^(ARF) and p53 proteins and the therapeutic efficacy of H101 on nasopharyngeal carcinoma

作　　者：李永强[1] 胡晓桦[1] 谢伟敏[1] 刘志辉[1] 周文献[1] 陆永奎[1] 岑洪[1] 黄鼎智[1] 谭晓虹[1] 廖小莉[1] 

机构地区：[1]广西医科大学肿瘤医院化疗一科,南宁530021

出　　处：《肿瘤》2007年第5期390-392,401,共4页Tumor

摘　　要：目的:观察肿瘤组织p14ARF、突变型p53蛋白表达状态与E1B缺陷型腺病毒治疗鼻咽癌疗效的关系,探讨E1B缺陷型腺病毒(简称H101)基因治疗的作用机制。方法:应用免疫组织化学方法对36例H101治疗的晚期鼻咽鳞癌病例进行肿瘤组织p14ARF、突变型p53蛋白检测,分析肿瘤组织p14ARF、突变型p53蛋白表达与H101临床疗效的关系;结果:突变型p53和p14ARF蛋白在36例晚期鼻咽鳞癌中总阳性表达率分别为55.6%和44.4%;突变型p53+p14ARF+(即p14ARF蛋白无缺失)患者均无治疗有效病例;突变型p53+p14ARF-(即p14ARF蛋白有缺失)患者中有4例有效;结论:对于p53基因无突变的恶性肿瘤,p14ARF基因缺失可能是H101能在肿瘤细胞内有效复制并杀死肿瘤细胞的一个重要影响因素。Objective ： To investigate the relationship between the expressions of p14^ARF and p53 protein and the therapeutic efficacy of E1 B-deleted adenovirus （ H101 ） on nasopharyngeal carcinoma and to explore the mechanism of the action of H101. Methods： The expressions of p14^ARF and p53 proteins in 36 cases of advanced nasopharyngeal carcinoma were detected by immunohistochemical method. The relationship between the expression of p14^ARF and mutant p53 protein and the therapeutic efficacy of H101 were analyzed. Results： The total positive rates of mutant p53 and p14^ARF proteins were 55.6% （20/36） and 44.4% （16/36） in advanced nasopharyngeal carcinoma, respectively. The total response rate of 36 patients after treated with H101 was 47.1%. Patients with positive p53 and p14^ARF expressions （p53^＋ p14^ARF ） had no response to H101 treatment. H101 treatment was effective in 4 patients with positive p53 protein expression and negative p14ARF expression （ p53^＋p14^ARF）. Conclusion： The loss of p14 ARF gene is an important factor for tumor-killing action of H101 on malignant tumor cells with nop53 gene mutation.

关 键 词：鼻咽肿瘤 肿瘤抑制蛋白质P53 肿瘤抑制蛋白质p14^ARF H101 

分 类 号：R739.6[医药卫生—肿瘤]